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Abstract
Background: Although the complete genome sequences of a large number of organisms have
been determined, the exact proteomes need to be characterized. More specifically, the extent to
which post-translational processes such as proteolysis affect the synthesized proteins has remained
unappreciated. We examined this issue in selected protein phosphatases of the protease-rich
malaria parasite, Plasmodium falciparum.
Results: P. falciparum encodes a number of Ser/Thr protein phosphatases (PP) whose catalytic
subunits are composed of a catalytic core and accessory domains essential for regulation of the
catalytic activity. Two examp l e s  o f  s u c h  r e g u l a t o r y  d o m a i n s  a r e  f o u n d  i n  t h e  C a +2-regulated
phosphatases, PP7 and PP2B (calcineurin). The EF-hand domains of PP7 and the calmodulin-binding
domain of PP2B are essential for stimulation of the phosphatase activity by Ca+2. We present
biochemical evidence that P. falciparum generates these full-length phosphatases as well as their
catalytic cores, most likely as intermediates of a proteolytic degradation pathway. While the full-
length phosphatases are activated by Ca+2, the processed cores are constitutively active and either
less responsive or unresponsive to Ca+2. The processing is extremely rapid, specific, and occurs in
vivo.
Conclusions: Post-translational cleavage efficiently degrades complex full-length phosphatases in
P. falciparum. In the course of such degradation, enzymatically active catalytic cores are produced
as relatively stable intermediates. The universality of such proteolysis in other phosphatases or
other multi-domain proteins and its potential impact on the overall proteome of a cell merits
further investigation.
Background
The cellular proteome, the end product in the flow of
genetic information in biology [1], is generally well pre-
dicted from the genome sequence [2]. The initially trans-
lated polypeptides, however, may undergo a variety of
post-translational modifications that must be determined
experimentally [3,4]. A major post-translation event in the
life of a protein is proteolytic processing [5]. Although
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proteolysis is undoubtedly responsible for the general
degradation and turn over of all proteins, it often consti-
tutes a physiologically important mechanism of biologi-
cal regulation for specific proteins and pathways. Among
the best studied examples are: the production of enzymes
from zymogens (such as trypsin from trypsinogen) [6],
generation of active caspases from procaspases [7], and
cleavage of viral polyproteins to generate functional pro-
teins [8]. Clearly, in such cases, the processed products
have a half-life long enough to be physiologically useful.
The existence of multiple proteases in all living cells that
differ in specificity, kinetics and regulation [5] further sug-
gests that their roles may extend beyond being purely deg-
radative. In spite of its potential importance, however, the
impact of proteolytic processing on the global proteome
has remained under-investigated.
P. falciparum is a protozoan parasite of the Apicomplexan
family and causative agent of deadly malaria [9]. Based on
its genome sequence, P. falciparum is predicted to contain
only about 5,500 proteins, as compared to about 40,000
of its human victim [10]. The parasite goes through a
complex series of life stages spanning asexual and sexual
stages in the human and mosquito hosts, respectively, and
marked by stage-specific up- and down-regulation of
many genes. Recent DNA microarray studies have
revealed an intricate continuum of transcriptional regula-
tion of the vast majority of parasitic genes over the 48-
hour developmental cycle in human erythrocytes [11,12].
Because of the high activity of proteases in the parasite, we
reasoned that proteolytic processing may represent a
major post-translational event in this organism.
In this communication, we document post-translational
processing for two Ca+2-activated serine/threonine (Ser/
Thr) protein phosphatases of P. falciparum, namely PP2B/
calcineurin and PP7/RdgC. These two enzymes possess
common as well as contrasting features. Protein phos-
phatase 2B, also known as calcineurin (and called protein
phosphatase 3 in the new nomenclature), is a Ca+2-stimu-
lated Ser/Thr phosphatase that plays important roles in
various biochemical pathways such as T-cell signalling
[13,14]. The holoenzyme is a heterodimer composed of
the catalytic subunit A (calcineurin A or CnA) and the reg-
ulatory subunit B (CnB). In addition to the catalytic
domain, CnA contains a CaM (calmodulin)-binding
domain, a CnB-binding domain and an autoinhibitory
domain [15-21]. The CnB subunit itself is a CaM-like
Ca+2-binding protein that contains four high-affinity
Ca+2-binding EF hands [15,16]. Binding of Ca+2 to CnB
stimulates phosphatase activity, although to a lesser
extent than when CaM is also present [15,16,19,22].
Finally, CnB is also required for the inhibition of cal-
cineurin by cyclophilin-cyclosporin A (Cyp-CsA) complex
[23]. Crystal structures of calcineurin and its complex with
CyP-CsA have been solved [15,16,24,25] and thus, the
mutual interacting domains and amino acid residues are
well-defined. PP7 is a Ca+2-activated EF-hand phos-
phatase, orthologs of which have been characterized in
Drosophila and human [26-28].
Our results presented here suggest that the catalytic subu-
nits of both phosphatases are produced as active full-
length polypeptides but are subsequently trimmed to
shorter active proteins that are also enzymatically active
but have lost important regulatory domains.
Results
Characterization and recombinant expression of PfPP2B 
(calcineurin)
The P. falciparum sequence database (PlasmoDB) shows
that the putative homologs of both subunits of cal-
cineurin exist in the parasite, although the predicted CnA
sequence has undergone revisions over the last few years.
We will refer to the P. falciparum subunits with a Pf prefix,
viz., PfCnA and PfCnB. Using specific oligonucleotide
primers both cDNAs were amplified by RT-PCR, cloned
and sequenced; the accession numbers for PfCnA and
PfCnB were PF08_0129 (PlasmoDB) and AAO33818
(GenBank) respectively. Multiple alignments of selected
CnA and CnB homologs are presented in Figs. 1 and 2,
respectively, which show the high homology of the P. fal-
ciparum sequences with the others including those of Tox-
oplasma gondii, especially in the functionally conserved
domains. The Apicomplexan enzymes are homologous to
the α and γ isoforms of CnA rather than β, because they
lack the N-terminal polyproline motif that is a conserved
feature of the β isoform. The minimal catalytic core of Ser/
Thr phosphatases of the PPP family (i.e., essentially all
Ser/Thr phosphatases except PP2C) is about 230 amino
acid long and is equivalent to the bacteriophage lambda
phosphatase [29,30]. In PfCnA this region roughly corre-
sponds to residue 43–285 and contains all the PPP signa-
ture motifs and conserved residues known to be
important in catalysis (Fig. 1). Based on homology to the
human CnA, the putative CnB-binding and CaM-binding
regions of PfCnA span residues 328–390 and 390–414
respectively (Fig. 1). Interestingly, the PfCnA sequence has
an approximately 130-residue insert between these two
regions. The only other well-characterized Apicomplexan
CnA, that of Toxoplasma gondii, also contains an insert in
the same position that is about 38-residue long (Fig. 1).
Obviously, regardless of their role, these peptide inser-
tions do not disrupt the functions of the CnB- and CaM-
binding domains.
To characterize the biochemistry of the P. falciparum cal-
cineurin, both subunits were expressed in the E. coli-pET
system and purified by affinity chromatography as
described in Methods. The relative mobility (Mr) ofBMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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Sequence similarity and cleavage sites of the plasmodial calcineurin A (CnA) subunit Figure 1
Sequence similarity and cleavage sites of the plasmodial calcineurin A (CnA) subunit. The P. falciparum (Pf) CnA sequence has 
been described in the Results. The accession numbers of other CnA sequences are: T. gondii (Tg) AAM97278, Paramecium 
tetraurelia (Pa) AF014922, H. sapiens (Hs) NP_000935. The sequences were aligned using the ClustalW program at the Euro-
pean Bioinformatics Institute (EMBL) server, and later refined by visual inspection. The numbers of amino acid residues are 
shown on the right. Residues that are identical or conservatively replaced (ST, AGILMV, DE, HKR, NQ, FWY) in all four 
sequences are highlighted in gray. The catalytic core, the CnB-binding, CaM-binding and the autoinhibitory domains are so 
marked based on studies of human CnA [15, 16, 19, 21, 25]. The catalytic domain is boxed. Residues that interact with the 
CsA-CyP complex are asterisked [24, 25]. The cleavage site of the plasmodial enzyme is marked by the closed triangle 
(between E527 and R528). Antibodies were made against synthetic peptides of the sequence TEEPPDYKALRDHLKKEGR, 
NCSMNDTDEGINDIV and RTLRKENELIVQLKGCSPG as shown, and used in immunoblot analysis in Fig. 3. The insertions in 
the Plasmodium and Toxoplasma sequences have been deleted for the sake of multiple alignment and space, but are shown on 
the bottom; the open triangle marks their location. The % numbers at the end represent amino acid identities of the Plasmo-
dium sequence with the others.
       Antibody  CnA-1 
Pf     ------PKNDRQVKDVEPPPAKPLSLELLYPNGTEEPPDYKALRDHLKKEGRIRKEDCLDIIKKVIDIVS  70 
Tg     ------PLHDRVVTSVQPPPAQPLKHSLLYPSGPANPPNWQELKSHLQREGRLSKEDCLELIKNVTEITS  70 
Pa     ------PANDRHVKTLKPPPHRPLMRNLMFPDKLKNKPDWKLLRDHLQKEGRVSKEDLYKLVGDCNKLLK  70 
Hs     ----KLSTTDRVVKAVPFPPSHRLTAKEVFDN--DGKPRVDILKAHLMKEGRLEESVALRIITEGASILR 73
    Catalytic  domain
Pf     NEPNLLRLKDPITIVGDIHGQYYDLLKLLE--VGGNPDHTQFLFLGDYVDRGSFSIEVLLLLYALKINFP 138 
Tg     NEPNLLRLNDPITVVGDIHGQFYDLLKLLD--VGGDPDTTQYLFLGDYVDRGSFSIEVLLLLYAIKLNHP 138 
Pa     NEGNVIYLQDPLTVVGDIHGQYYDLLKLLEPKVGGNPETTKYLFLGDFVDRGSYSIEVIILLYAIKLNYP 140 
Hs     QEKNLLDIDAPVTVCGDIHGQFFDLMKLFE--VGGSPANTRYLFLGDYVDRGYFSIECVLYLWALKILYP 141
Pf     DRIWLIRGNHECRQMTTFFNFRDECEYKYDIVVYYAFMESFDTIPLSAVINGKFLGVHGGLSPDLILLNQ 208 
Tg     TRVWLLRGNHECRQMTSFFNFRDECECKYDMTVYFAFMEAFDSLPLAAVINGKFLALHGGLSPELKVLSQ 208 
Pa     NTVYFLRGNHECRQLTAFFNFKEECLYKYDQETYDMLMDSFDLFPLACIINSKFIAIHGGISPDLKSLED 210 
Hs     KTLFLLRGNHECRHLTEYFTFKQECKIKYSERVYDACMDAFDCLPLAALMNQQFLCVHGGLSPEINTLDD 211 
Pf     ICSFTRFQEPPRSGIFCDILWSDPIDEDKEEHTIQTESYF-PNDIRGCSYFFGYNAATTFLEKNGLLSII 277 
Tg     IGGVNRFQEPPRGGLFCDLLWADPLDESKDDVGQSPEDSFTPNDVRGCSFFFGYSAASKFLDRNGLLSVL 278 
Pa     IKRLDRYHEPPRSGLLCDLLWSDPVDQDQGNMDGQWKG----NEVRGCSWFFGNEAASKFLQKNNLISII 276 
Hs     IRKLDRFKEPPAYGPMCDILWSDPLEDFGNEKTQEHFTH---NTVRGCSYFYSYPAVCEFLQHNNLLSIL 278 
             [<---  CnB-binding---- 
Pf     RAHEAQLEGYKMHQTNLKTGFPIVITIFSAPNYCDVYNNKGAVLKFDSNTLNIQQFSFSPHPYHLPNFMN 347 
Tg     RAHEAQLEGYKMHQTNQKTGFPTVITIFSAPNYCDVYNNKGAVLKFENNTLNIQQFNFSPHPYHLPNFMD 348 
Pa     RAHEAQLDGYKMHRWHGGKDFPVVITIFSAPNYCDVYNNKGAVIKFENNTLNIQQFQYTPHPYLLPNFMD 346 
Hs     RAHEAQDAGYRMYRKSQTTGFPSLITIFSAPNYLDVYNNKAAVLKYENNVMNIRQFNCSPHPYWLPNFMD 348 
              *  **           ***** 
   --- CnB-binding -------------------------------->]             [<----- 
           Cleavage 
            Antibody CnA-2             
Pf     LFTWSLPFVSEKVTEMLYSLLN-CSMNDTDEGINDIDGRKTKDVGQVSKE-------------RTDTLRK 534 
Tg     VFTWSIPFVSEKVTEMLYGILN-PSIDDDED---------------LSKE-------------RADALRK 427 
Pa     IFTWSIPFVAEKVTEMLYNLLQVGDQVDDEEVNEEDIKQFKEMTQQQNKQFDKQSTGGSNTAKNTEKLKK 416 
Hs     VFTWSLPFVGEKVTEMLVNVLNICS---DDELGSEE--------DGFDGA---------TAAARKEVIRN 398
          ** **  * 
   -CaM-binding ->] Antibody CnA-3 
Pf     KVQSVGRLMRVFRTLRKENELIVQLKGCSPGYRIPVGLLLSGKEGLEN-------------------ELE 585 
Tg     KVQSVGRLMRVFKTLRQENELIVRLKGCTPGHRIPVGLLLQGREGIAN-------------------ELD 478 
Pa     KIIFVANMIKMQKTLREQSESIIYLKGACPDKRLPRGVLTAGKSAIMD---------------------- 464 
Hs     KIRAIGKMARVFSVLREESESVLTLKGLTPTGMLPSGVLSGGKQTLQSATVEAIEADEAIKGFSP---QH 465
                 <----------------------- Autoinhibitory domain --  
               
Pf     KFTKVKEIDSINEKRPSNE 604 (100%) 
Tg     KFENAKQIDLMNERRPDGGSSSR 501 (70%) 
Pa     ALADFNLARNADIVNEKMPTVTQTPQQSISINKSTNSTSSNTKKK 509 (52%) 
Hs     KITSFEEAKGLDRINERMPPRR--DAMPSDANLNSINKALTSETNGTDSNGSNSSNIQ 521 (47%) 
   ---------------->   
Pf insert: 
382VLPKEVIQILNYIEENNKRINEMNFNNNDDNVQYEDNGPYINQSNNNNNNNNKDNKFDDITYDDHKKEKDKRNKISSNGNMQ
DNNQLYDHSEGHNNYNDEDEFFKNVKKTDTNNNNNNEEEDEEEDEEEEE
512
Tg insert:
379DEDVDDVELPPAVLSIMKAHLPSDEASGQRHPPAGDNR
416BMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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PfCnA and PfCnB in SDS-PAGE were 69 k and 21 k,
respectively, which roughly matched their predicted sizes
of 70 kDa and 20 kDa plus about 2 kDa added for the His
tags at the N- and C-terminus, respectively (Figs. 3,4; lane
3).
Proteolytic processing of P. falciparum calcineurin in vivo 
and in vitro
We previously reported a protein phosphatase activity
purified from erythrocyte-grown P. falciparum that exhib-
ited calcineurin-like properties [31]. The activity was stim-
ulated by Ca+2 and calmodulin, and was inhibited by the
cyclophilin-CsA (cyclosporin A) complex, which are hall-
marks of calcineurin. Strangely, however, the polypeptide
pattern of the parasitic preparation, as reported before
[29], does not match the sizes of the full-length recom-
binant PfCnA and PfCnB described here. Whereas the
recombinant PfCnA and PfCnB are 70 and 20 kDa, respec-
tively (Figs. 1,2,3,4), the previously published calcineurin
preparation was composed of 55 kDa and 16 kDa
polypeptides on the basis of mobility in SDS-PAGE [31].
To determine whether we were dealing with multiple spe-
cies of calcineurin in P. falciparum, we subjected each of
these proteins to peptide mass spectroscopic analysis fol-
lowed by trypsinization. The 55 kDa band and the recom-
binant PfCnA indeed showed common peptides, as did
the 16 kDa band and recombinant PfCnB, suggesting that
these proteins had common sequences. The simplest pos-
sibility at this point was that the 55 kDa and the 16 kDa
bands were fragments of full-length PfCnA and PfCnB,
respectively, perhaps generated by proteolytic processing.
In what follows, we provide further evidence to confirm
this.
We first developed three peptide antibodies each for
PfCnA and PfCnB proteins. The peptides corresponded to
N-terminal, internal and C-terminal sequences – and were
designated 1, 2 and 3, respectively. For example, in PfCnA,
they were named CnA-1, CnA-2 and CnA-3, etc. These
peptides are marked in the PfCnA and PfCnB sequences in
Fig. 1 and Fig. 2, respectively. We reasoned that if proteol-
ysis was the underlying mechanism, then it had to be cat-
alyzed by parasitic proteases, since the recombinants
expressed in E. coli were full-length. To investigate if the
conversion was time-dependent, the parasitic pellet
obtained after saponification of the infected RBC was held
at room temperature for increasing lengths of time, and
then boiled in SDS sample buffer [32], followed by
immunoblot analysis using the three antibodies. These
results are shown in the immunoblot panels of Figs. 3 and
Sequence similarity and cleavage sites of the plasmodial calcineurin B (CnB) subunit Figure 2
Sequence similarity and cleavage sites of the plasmodial calcineurin B (CnB) subunit. The accession number of the CnB subunits 
are: P. falciparum (Pf) AAO33818, T. gondii (Tg) AAM97279, H. sapiens (Hs) NP_000936. The cleavage site is indicated by the 
closed triangle (between K32 and R33). The four EF-hand motifs are boxed. Antibodies were made against synthetic peptides 
of the sequence QKDLLQAANFSETDIK, GITKLASSTDDFQKKK and DMISHMDVGNKLKLE as shown, and used in immuno-
blot analysis in Fig. 4. Residues that contact CyP-CsA are asterisked [24, 25]. The % numbers at the end represent amino acid 
identities of the Plasmodium sequence with the others.
                  Cleavage 
        Antibody  CnB-1 
Pf-CnB    MGNTQAILSEKDQKDLLQAANFSETDIKKMYKRFIELDTNKNGQLDPNELFDVPEICDNP 60 
Tg-CnB    MGNAQGRLSPQEQMDLLHAANFSERDLKKLYKRFRALDTNQNGELDTHELFDVPELADNP 60 
Hs-CnB    MGNEAS--YP-----LEMCSHFDADEIKRLGKRFKKLDLDNSGSLSVEEFMSLPELQQNP 53 
                                                                *  * 
             Antibody CnB-2      
Pf-CnB    LVKRVISIFDSNSDGKVSFVEFLVGITKLASSTDDFQKKKFAFDVYDINKDGMISNGELF 120 
Tg-CnB    LVKRVLSIFDTNGDGKVSFVEFLVGLSKLAANTDEFQKTKFAFDVYDINKDGSISNGELF 120 
Hs-CnB    LVQRVIDIFDTDGNGEVDFKEFIEGVSQFSVKGDKEQKLRFAFRIYDMDKDGYISNGELF 113 
                      Antibody CnB-3      
Pf-CnB    TVMKMMVGNNLNDTQLQQLVDRTILQADKDGDGMISFEEFKDMISHMDVGNKLKLEL 177 (100%) 
Tg-CnB    AVMKMMVGSNLNDQQLQQLVDRTIVQADKDGDGMISFDEFREMVSHIDIADKLRVDL 177 (75%) 
Hs-CnB    QVLKMMVGNNLKDTQLQQIVDKTIINADKDGDGRISFEEFCAVVGGLDIHKKMVVDV 170 (50%) 
               **  ***                                       * BMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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4, for PfCnA and PfCnB, respectively. It is clear that for
both proteins, all three antibodies were able to detect the
full-length PfCnA and PfCnB (70 and 20 kDa, respec-
tively) (in lanes numbered 1), demonstrating the activity
of the antibodies in immunoblot. Even the freshest para-
sites, however, additionally contained significant
amounts of the processed proteins. The processed 55 kDa
band of PfCnA could be detected with N-terminal CnA-1
and internal CnA-2 antibodies (Fig. 3) but not with the C-
terminal CnA-3 antibody. Reciprocally, the processed 16
kDa fragment of PfCnB could be detected with the inter-
nal CnB-2 and the C-terminal CnB-3 antibodies but not
with the N-terminal CnB-1 antibody (Fig. 4). The ratio of
intensities of the full-length and the processed bands from
multiple experiments revealed that 40–50% of CnA and
20–35% of CnB in the freshly isolated parasite could be
found processed. These results suggested that most of the
processing had already occurred in vivo. Essentially all the
full-length protein disappeared by 5 min with concomi-
tant increase of the processed bands, attesting to the high
efficiency of processing. As shown in the immunoblot of
Fig. 5 (lanes CnA and CnB), the processed fragments
could be detected even when the infected erythrocytes
were directly boiled in SDS sample buffer and analyzed in
SDS-PAGE without wasting any time for the isolation of
the parasite. We infer that the processing of PfCnA and
PfCnB, regardless of its mechanism, occurs in vivo.
To pave the way to the mechanism of the processing, we
attempted to establish an in vitro processing reaction. We
reasoned that if the processing is a post-translational
event, it may be possible to reproduce it in vitro using the
bacterial recombinant proteins and catalytic amounts of
P. falciparum extract as the potential source of the process-
ing activity. This was indeed found to be true. As shown in
the immunoblots in Figs. 3 and 4 (lanes numbered 4),
substantial portions of the recombinant PfCnA and
PfCnB were converted to the shorter fragments whose size
and antibody reactivity matched to those of the corre-
sponding in vivo processed bands (compare lane 1 or 2
with lane 4 in a given antibody panel). The His-tags added
~2 kDa to the molecular weight of the recombinants;
hence their slower mobility as observed. The presence of
the tags in the processed recombinant bands was
Processing of PfCnA in vivo and in vitro Figure 3
Processing of PfCnA in vivo and in vitro. Immunoblot analysis was performed with peptide antibodies CnA-1, -2 and -3 
(described in Fig. 1) and with the anti-His tag antibody. The lanes contained the following samples: 1 = 50 µg total protein from 
freshly isolated parasite; 2 = same as 1 except that the parasite was incubated at room temperature for 5 min; 3 = 120 ng of 
purified His-tagged (recombinant) PfCnA; 4 = as in lane 3 but following incubation with parasite extract; 5 = as in lane 4 except 
that the incubation mixture also contained protease inhibitor cocktail. In the right panel (Stain) higher quantities (5 µg) of the 
same recombinant protein samples of the corresponding lane numbers were analyzed and the gel stained with Coomassie Blue 
R250. The full-length and processed bands are indicated as F and P, respectively. Size markers are indicated on the two sides. 
Details are given in Methods.
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confirmed by their reactivity to the respective anti-tag
antibodies (panels labeled "His-tag" in Fig. 3 and 4),
which further proved that the N-terminus of PfCnA and
C-terminus of PfCnB were intact in the processed frag-
ments. In summary, the in vitro cleavage appeared to
mimic in vivo processing with respect to Mr in SDS-PAGE
and antibody cross-reactivity.
To gain a preliminary knowledge of the nature of the puta-
tive protease, we attempted to inhibit the in vitro process-
ing by a cocktail of protease inhibitors described under
Methods. This caused a retardation of the processing,
although a complete inhibition could not be achieved
(Figs. 3 and 4, all lanes numbered 5; compare with
unprocessed bands in lanes numbered 4 in the same
panel). As antibodies may vary in efficiency and may not
provide a good quantitation of the antigens, the cleavage
product of the recombinant proteins were also analyzed
by direct staining. Results in Fig. 3 and 4 (Panels labeled
"Stain") showed that the stained pattern strongly matched
the immunoblot of the corresponding samples, thus vali-
dating the conclusions. It is also to be noted that for both
PfCnA and PfCnB, the other half of the protein could not
be detected, suggesting that it is rapidly proteolyzed into
smaller fragments. Together, these results strongly suggest
that PfCnA and PfCnB are processed by a highly efficient
parasitic protease or proteases in vivo.
The reactivity of the processed bands to the peptide anti-
bodies provided an approximate location of the process-
ing sites (Fig. 1 and 2). The availability of relatively large
quantities of the bacterial recombinant proteins
prompted us to determine the processing site more accu-
rately by either mass spectrometric analyses or N-terminal
sequence analyses of the C-terminal fragments. For
PfCnA, where the 55 kDa processed product corre-
sponded to the N-terminus (Fig. 1), the best choice was to
subject it to an accurate mass determination. This led to
the identification of the major cleavage site to be between
Glu527 and Arg528 (Fig. 1). For PfCnB, the processed
product was the C-terminal fragment (Fig. 2), which was
subjected to N-terminal sequence analysis. This led to the
placement of the major cleavage site between Lys32 and
Arg33 (Fig. 2), which was also confirmed by the determi-
nation of mass.
Thus, processing of PfCnA occurred between the putative
CnB-binding and CaM-binding domains (Fig. 1). In other
words, the processing led to the loss of the putative CaM-
binding domain, while the rest of the protein remained
intact.
Altered regulation of parasitic calcineurin as a result of 
processing
Once we roughly mapped the processing sites, we set out
to determine the potential effects of processing on
Processing of PfCnB in vivo and in vitro Figure 4
Processing of PfCnB in vivo and in vitro. Immunoblot analysis was performed with the antibodies CnB-1, -2 and -3 (described in 
Fig. 2) and the anti-His tag antibody on the following samples. 1 = total protein (60 µg) from freshly isolated parasite; 2 = same 
as lane 1 except that the parasite was incubated at room temperature for 5 min; 3 = purified recombinant His-tagged PfCnB 
(120 ng); 4 = as in lane 3 but after incubation with parasite extract; 5 = as in lane 4 except that the incubation mixture also con-
tained protease inhibitor cocktail. In the right panel (Stain) higher quantities (5 µg) of the same recombinant protein samples of 
the corresponding lane numbers were analyzed and the gel stained with Coomassie Blue R250. The full-length and processed 
bands are indicated as F and P, respectively. Size markers are indicated on the two sides. Details are given in Methods.
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enzymatic activity. The phosphatase activities of the full-
length and cleaved recombinants were determined under
various combinations of CaM and Ca+2, and presented in
Table 1. The properties of the purified parasitic enzyme
(processed) were described previously [31]; they were fur-
ther confirmed here (data not shown) and found to be
essentially identical to those of the processed recom-
binant enzyme. The following important points emerge
from these results. First, the full-length holoenzyme had a
slightly lower basal activity than the processed one (1.2 U
vs. 2.6 U). We believe that this is because PfCnA has an
autoinhibitory (AI) domain at the C-terminus (Fig. 1).
Although the exact length of the AI domain in PfCnA
needs to be determined, deletion of the corresponding
region from human CnA led to increased activity [19,21].
We then tested the effect of proteolysis on the responsive-
ness of the recombinant enzyme to Ca+2 and CaM, and in
general, the holoenzyme was found to be more responsive
than the processed one. Thus, while the processed enzyme
was unresponsive to Ca+2, the full-length holoenzyme was
Processed phosphatases in vivo Figure 5
Processed phosphatases in vivo. P. falciparum-infected eryth-
rocytes (RBC) at 15% parasitemia were centrifuged at 12,000 
× g in cold for 1 min and the pellet resuspended in 50 µl SDS 
sample buffer [32], followed by boiling (5 min). The undis-
solved material (mostly RBC skeleton and parasitic hemo-
zoin) was removed by centrifugation and the supernatant 
(250 µg protein per lane) analyzed by immunoblot using 
internal peptide antibodies against the indicated proteins 
(CnA-2, CnB-2 and PP7-2, respectively; compare with the 
bands in Fig. 3, 4, and 7, respectively). The two bands (full-
length and processed) in each lane are indicated by arrow-
heads. Lane U represents a similarly processed sample from 
uninfected RBC, probed with a 1:1:1 mixture of all three anti-
bodies. The background bands are due to nonspecific binding 
of the IgG's to various RBC components, the darkest of 
which is marked by the open circle. The size markers are 
shown on the left.
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Table 1: Altered regulation of P. falciparum phosphatases upon 
processing
Additionsa Full-length enzymeb Processed enzymec
Calcineurin
None 1.2 ± 0.5 U 2.6 ± 0.6 U
Ca+2 8.2 ± 1.0 U 2.8 ± 0.8 U
CaM 25.4 ± 4.8 U 12.5 ± 2.0 U
Ca+2, CaM 84.6 ± 8.0 U 21.5 ± 2.8 U
Ca+2, CaM, Mg+2 88.0 ± 9.5 U 23.6 ± 2.9 U
Ca+2, CaM, OA 82.0 ± 9.6 U 20.0 ± 3.0 U
Ca+2, CaM, CyP, CsA 4.5 ± 0.8 U 6.1 ± 0.7 U
PP7
None 5.2 ± 0.9 U 4.8 ± 0.6 U
Mg+2 8.5 ± 1.1 U 5.1 ± 0.7 U
Mn+2 14.6 ± 1.8 U 68.5 ± 8.5 U
Ca+2 6.4 ± 0.8 U 4.8 ± 0.8 U
Mn+2, Ca+2 60.0 ± 8.0 U 70.8 ± 9.0 U
Mn+2, Ca+2, CaM 60.8 ± 7.5 U 69.2 ± 8.2 U
Mn+2, Ca+2, OA 68.8 ± 8.1 U 70.6 ± 9.5 U
aThe phosphatase assays using recombinant enzymes and 32P-labeled 
phosphohistone substrate were carried out as described under 
Methods. The numbers represent nanomoles of 32Pi liberated per 
minute per mg enzyme (protein). For calcineurin, essentially similar 
relative response was observed using the RII peptide as substrate 
(data not shown). Where indicated, the following additions were 
made at the indicated concentrations: Ca+2, Mg+2, Mn+2 (2 mM each), 
calmodulin (CaM, 40 units per ml), CyP (recombinant PfCyP19, 1 
µM), cyclosporin A (CsA, 1 µM), OA (0.2 µM) [30]. bThe full-length 
enzymes were purified recombinant proteins; for calcineurin, a 1:1 
molar mixture of recombinant tagged PfCnA and PfCnB was used. 
cThe processed calcineurin was a 1:1 molar mixture of the 55 kDa 
and 16 kDa fragments of PfCnA and PfCnB, respectively, obtained 
after proteolytic processing (Fig. 3, 4). Similarly, the processed PfPP7 
was the ~38 kDa product obtained by proteolysis of recombinant 
PfPP7 (Fig. 7). The activity values of the native (processed) enzymes, 
purified from the parasite [31, 33], were very similar to the processed 
recombinant enzymes and, therefore, were not shown to conserve 
space. Each value is a mean from three experiments with the standard 
error as shown.BMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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stimulated about 7-fold (Table 1). CaM stimulated the
full-length enzyme nearly 24-fold, while stimulating the
processed enzyme by about 5-fold. Although the putative
CaM-binding domain of PfCnA was lost upon processing
(Fig. 1), the processed holoenzyme obviously retained
some ability to interact with CaM. The residual interaction
may be mediated by another uncharacterized domain of
PfCnA or by PfCnB. A combination of Ca+2 and CaM led
to a 9-fold stimulation of the processed enzyme but an 80-
fold stimulation of the full-length enzyme. Thus, the full-
length enzyme showed a much greater activation by Ca+2
and CaM. Although the regulation of calcineurin by Ca+2
and CaM is a complex process [19], the substantially
lower response of the processed enzyme is most easily
explained by the loss of one Ca+2-binding EF hand in the
processed PfCnB subunit and by the loss of the CaM-bind-
ing domain of the PfCnA subunit. Essentially similar rela-
tive activities before and after processing were obtained
when the calcineurin-specific peptide substrate RII was
used, demonstrating that the substrate-specificity of the
enzyme was left intact through processing (data not
shown). In summary, the proteolytic loss of selected regu-
latory domains of the P. falciparum calcineurin led to
altered regulation while keeping the basic enzymatic func-
tion intact.
Finally, the full-length recombinant P. falciparum holoen-
zyme was found to be sensitive to cyclophilin-CsA using
recombinant  Plasmodium  cyclophilin 19 (Cyp19) in
assays described previously [31] and its Ki for Cyp19 was
measured to be 360 nM, which was comparable to that of
the native processed enzyme (410 nM) [31]. PfCnB was
absolutely needed for this sensitivity as recombinant
PfCnA alone was resistant, consistent with similar results
with mammalian calcineurin [23]. Thus, processing had
little effect on the CsA-sensitivity of the plasmodial
enzyme.
P. falciparum protein phosphatase PP7 and its processed 
form, PPJ
In this section we report the biochemical characterization
and processing of a second Ca+2-stimulated phosphatase
in P. falciparum. Sequence homology (not shown) placed
it in the Drosophila RdgC/ human PP7 phosphatase family
and therefore, we named it PfPP7 [7,8,33]. Using RT-PCR
with nested primers, we confirmed that the cDNA
sequence predicted in PlasmoDB was correct (Accession
number PF14_0224), and thus, we only show the concep-
tually translated protein sequence and its relevant
domains (Fig. 6). As shown, the cDNA is made up of 16
exons whereby the largest exon encodes most of the cata-
lytic core. We cloned the full-length cDNA in the pET-15b
vector and expressed the 959 amino acid long protein in
E. coli essentially as described earlier for PfCnA. As
detailed later, the 112 kDa recombinant PfPP7 protein
exhibited phosphatase activity in vitro against a variety of
substrates, including 32P-phosphohistone and pNPP, and
required Mn+2 and Ca+2 for optimal activity, supporting its
PP7 identity.
In previous work [33], we had cloned a portion of this
cDNA and showed that the corresponding protein,
expressed in E. coli, was an active protein Ser/Thr phos-
phatase, which we named PfPPJ (Accession No.
AAF19176). The PfPPJ sequence is demarcated within
PfPP7 in Fig. 6, and the biochemical properties of the two
are compared in Table 1. The starting Met of the PfPPJ
ORF was in fact the internal in-frame Met232 of PfPP7.
Because the draft Plasmodium genome sequence available
at the time was missing a stop codon for the PfPP7 open
reading frame, one had to be added into the PCR primer
to generate the recombinant PfPPJ clone. While PfPP7
contains 959 amino acid residues, PfPPJ had only 294
residues; thus, recombinant PfPPJ in effect represented the
catalytic core of PfPP7, and lacked the regulatory EF hands
in the C-terminal half of PfPP7 (Fig. 6).
Interestingly, a parasitic protein band resembling the
recombinant PfPPJ was previously detected in P. falci-
parum lysates [33], which cross-reacted with an antibody
against the peptide EVIRETFEENQKLREK (PP7-2 in Fig.
6) near the C-terminus of PfPPJ, corresponding to resi-
dues 494–509 of PfPP7. To explain this, we hypothesized
that PfPPJ in the parasite might have been produced by a
post-translational processing of PfPP7, perhaps by a
proteolytic mechanism similar to the one seen for cal-
cineurin. To test this, we performed an essentially similar
series of experiments. First, the PP7-2 antibody [33] was
reused because the peptide is common to both PfPP7 and
PfPPJ sequences. Additional antibodies (PP7-1 and PP7-
2) were made against peptides that were in the PfPP7
sequences just outside of PfPPJ; these are all marked in
Fig. 6. Freshly harvested parasitic cell pellet was then
probed with these antibodies in immunoblot. Results
(Fig. 7) show that PfPP7 could indeed be detected at the
earliest time point, although PfPPJ was much more abun-
dant. The ratio of the PP7 and PPJ bands in lane 1 of PP7-
2 panel was 28:72, indicating that only about a third of
the total PP7 remained unprocessed. Upon further incu-
bation of the parasite pellet, PfPP7 completely disap-
peared and produced PfPPJ that could be detected by the
internal peptide antibody (PP7-2). Essentially similar
processing could be reproduced by incubating recom-
binant PfPP7 with small amounts of parasitic extracts as a
potential source of proteases (Fig. 7, lanes 3–5). Use of
protease inhibitor cocktail inhibited the processing to
some extent (ranging from 30–50%) but could not com-
pletely prevent it (Fig. 7, lanes numbered 5). The stained
gel pattern (Fig. 7, panel "Stain") was very similar to the
immunoblot with PP7-2, thus validating each other. TheBMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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cleavage was observed even when the infected erythro-
cytes were quickly boiled in SDS buffer and analyzed by
immunoblot (Fig. 5), confirming that the processing is
physiological and occurs in vivo.
As with PfCnA and PfCnB, the approximate location of
the PfPP7 cleavage sites could be gleaned from the reactiv-
ity pattern of the processed fragments with the peptide
antibodies and the His-tag antibody (Fig. 6 and 7). The N-
terminal cleavage site was then accurately determined by
N-terminal sequencing of the PfPPJ polypeptide obtained
by  in vitro cleavage of the recombinant PfPP7 (Fig. 6;
"Stain" panel). This sequence matched that of native
PfPPJ determined previously [33], and thus, the cleavage
site is between Asp231 and Met232 (Fig. 6). We then
attempted to determine the C-terminal cleavage site by
mass spectra of the PfPPJ produced by in vitro processing.
This produced a heterogeneous data (not shown),
indicating that the cleavage occurred at multiple peptide
bonds between Ser531 and Gly534. This is marked in Fig.
6, showing that the processing resulted in the loss of the
The sequence and cleavage sites of PfPP7 Figure 6
The sequence and cleavage sites of PfPP7. Panel A: The complete sequence of P. falciparum PP7 is shown. Peptides coded for by 
alternate exons are in bold. The PfPPJ sequence is boxed. Antibodies PP7-1, -2 and -3 were made against synthetic peptides of 
the sequence HKVLIKTKKMLEENIK, EVIRETFEENQKLREK, EKNSLWNNLYKQDKDK, respectively (as shown) and used in 
immunoblot analysis in Fig. 7. The two proteolytic cleavage sites are indicated; one between D231 and M232 (closed triangle), 
and the other and less precise site within the STEG sequence (broken line). Note that the cleavage essentially produces PPJ 
from PP7. The two EF-hand motifs are boxed in both panels A and B. Panel B: Sequence homology between the three PP7 
homologs of P. falciparum, Drosophila (RdgC) and human origin. The location of a 141-residue insert (not shown) in the Plasmo-
dium sequence is indicated by the open triangle; it is absent in the other homologs.
        A
MENYNIEDVVMIYGHKAIIESIQNVENVKSEIQPNKIYVGKYVNKKGYSDGTYRKKKIYTPQNDELVILCSYNSI  75 
KPYNEEESACTMIQKMFRGYQGRKSFHSFVCCTVWRKFDHIHEYITLNNHDEIYKPLIKTIKRDIKKGIIQFPSK  150 
           Antibody PP7-1
CFSSNSNQFSRVSTTSYESSNYNENVPRLKDKIDRTFATEMFHFFLTSKEIILPYNLVHKVLIKTKKMLEENIKS 225
  Cleavage
SVINLDMSKKSKDTKLIILGDVHGQLHDVLWLFNRFGIPSSTNIYIFNGDIADRGENATEIFILLFIFKLSCNDS  300 
VIINRGNHECSYMNEVYGFYNEVLSKYDNTIFDLFQNIFELLGLAVNVQNQIFVVHGGLSRYQDITLKEIDELDR  375 
KKQEILHPEQYEDIVIFDLLWSDPQKKEGIGGNARGNNCITFGPDVTEMFLKNNNLDILIRSHQVPKTLKGIESH  450 
                Antibody PP7-2
HEGKCITLFSASNYCNKIKNLGAAIIFNQDLTFEVQEYMSPSLEVIRETFEENQKLREKVLHCSKIVELEKNEQK  525 
   Cleavage              Antibody PP7-3
NNNKLSTEGLMNDIINCLSTIICNEKNSLWNNLYKQDKDKKGVVHINIWKEELGKLSKAKKVPWIYLCRKLKMIE  600 
DYHVNYNNILSRFKINYAPNEKFLNTEWKNECFEHLYEALLKADLSLRETLMVFDKNLDGKVSFAEFEQVLRDLN  675 
IDLSNEQIRILVRLINSNSLCNNTNLQENDKIDVAEFIGKMRVCYRLSINKDYVNNEKIQKLIETIGKHILSDSA  750 
DTANYHYKFYEENNERHNSERRKRSSVIKSVALFQKFKNYDNFGNGYLDYNDFVKAIKNFDMNKISKEVEFEVDD  825 
DILMELAKSIDITKSSKINFLEFLQAFYVVNKSKYSYVDEIWCHICTVIYENKVALKKCMKYLEDTMQGKITSIH  900 
FRYILLELNKILQEHNFEMNKPLTDEQIDLLAYTVETDDKVDYVEFFNSFKPTYIYSNN                  959 
        B
PfPP7 (648)RETLMVFDKNLDGKVSFAEFEQVLRDLNIDLSFEVDDDILMELAKSIDITKSSKINFLEFLQAF (715) 
RdgC  (532)VAIFNIIDADNSGEITLDEFETAIDLLVAHMPGAYSKAEMLEKCRMMDLNGDGKVDLNEFLEAF (599) 
HsPP7 (572)EIIFNAIDTDHSGLISVEEFRAMWKLFSSHYNVHIDDSQVNKLANIMDLNKDGSIDFNEFLKAF (639) BMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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EF-hand motifs that are considered important for Ca+2
binding.
When the catalytic properties of PfPP7 and PfPPJ were
compared important similarities and differences emerged.
While PfPPJ was able to dephosphorylate phosphohis-
tone as well as phosphorylase a  [33], PfPP7 preferred
phosphohistone. In the presence of Mn+2 and Ca+2 (1 mM
each), the specific activities of PfPPJ and PfPP7 were
respectively 205 and 18 units per mg enzyme with phos-
phorylase a as substrate, whereas the corresponding num-
bers were 72 and 60 with phosphohistone as substrate.
For this reason, we used phosphohistone as the substrate
in the rest of the paper, such as in Table 1 and Fig. 8. With
both PfPP7 and PfPPJ, very little activity was seen in the
absence of a divalent cation. With PfPPJ, Mn+2 alone was
sufficient to activate the enzyme to the fullest extent
(Table 1); Ca+2 did not cause any further activation. In
sharp contrast, PfPP7 had a lower basal activity that was
dependent on Mn+2 but was stimulated nearly 4-fold by
Ca+2 (Fig. 7); in other words, PfPP7 was a Mn+2-dependent
Ca+2-stimulated phosphatase. Mg+2 could not substitute
for Mn+2. While confirming the previous results of PfPPJ
[33], these results showed that unlike PfPPJ, the full-
length PfPP7 is indeed a Ca+2-stimulated enzyme, true to
this family of phosphatases [26]. It thus appears that Mn+2
is essential to impart proper folding to both enzymes for
their basal activity and that in PP7 further stimulation of
the Mn+2-containing enzyme is achieved by Ca+2 through
an allosteric mechanism. The lack of Ca+2-response in
PfPPJ is most easily explained by the loss of the proposed
EF hand sequences upon proteolytic cleavage (Fig. 6). We
do not know why the constitutively high Ca+2-independ-
ent activity of PfPPJ practically equals the Ca+2-stimulated
activity of PfPP7 (Table 1). However, it is possible that as
in the case of CnA, the C-terminus of PfPP7 has an autoin-
Processing of PfPP7 to PfPPJ in vivo and in vitro Figure 7
Processing of PfPP7 to PfPPJ in vivo and in vitro. Immunoblot analysis was performed with the antibodies PP7-1, -2 and -3 (Fig. 6) 
and anti-His tag antibody on the following samples: 1 = total protein (60 µg) from freshly isolated parasite; 2 = same as lane 1 
except that the parasite was incubated at room temperature for 5 min; 3 = purified His-tagged recombinant PfPP7 (120 ng); 4 
= as in lane 3 but after incubation with parasite extract; 5 = as in lane 4 except that the incubation mixture also contained pro-
tease inhibitor cocktail. The "Stain" panel analyzed reactions of the same lane numbers as above with higher amounts of protein 
(5 µg in lanes 3 and 4; 10 µg in lane 5); the gel was stained with Coomassie Blue. As indicated, the 112 kDa band is PfPP7 and 
the 38 kDa band approximates PfPPJ. The size markers are presented on the left and right. Details are given in Methods.
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hibitory effect on the phosphatase activity, and that the
binding of Ca+2 serves to change the conformation of this
domain such that the autoinhibitory property is lost.
Clearly, it will be interesting to determine whether PP7
has such an autoinhibitory domain.
Discussion
In this paper, we focus on two Ca+2-activated phos-
phatases of P. falciparum, namely calcineurin/PP2B and
PP7. Biochemical studies of recombinant enzymes
showed that both were highly Ca+2 dependent. The iden-
tities of the enzymes were established by sequence homol-
ogy as well as general family-specific biochemical traits.
For calcineurin, the diagnostic properties were: the ability
to dephosphorylated the RII peptide, Ca+2-dependence,
sensitivity to the CyP-CsA complex, and resistance to OA.
For PP7, the most relevant properties were: stimulation by
Ca+2 and resistance to OA. PP7 also needed additional
divalent cation for basal activity: while the human PP7
was shown to require Mg+2, the recombinant PfPP7
required Mn+2 instead. Interestingly, the catalytic subunits
of both the plasmodial enzymes contained large inser-
tions outside the catalytic cores and between two
regulatory modules. In PfCnA, the 131-residue insertion
was located roughly between the CnB-binding and the
CaM-binding domains (Fig. 1); and in PP7, the 141-resi-
due insertion was located between two EF hand motifs
(Fig. 6). Although the three-dimensional structure of PP7
has not been solved, the crystal structure of human cal-
cineurin suggests that there is enough space to accommo-
date the insertion. In PfCnA, the cleavage occurs within
the insertion, suggesting that this stretch of peptide may
have a disordered solvent-exposed structure, rendering it
particularly susceptible to proteolytic attack. As discussed
below, a significant finding of our study is the generation
of shorter, constitutively active and specific fragments of
these enzymes in vivo.
Most enzymes, including protein phosphatases, contain
defined catalytic and regulatory domains that are modular
in nature. Protein Ser/Thr phosphatases, in particular,
contain a highly conserved central catalytic core that is
necessary and sufficient for phosphatase activity
[30,34,35]. Most of the eukaryotic phosphatases contain
additional N-terminal or C-terminal extensions that serve
in regulatory roles [30,34-37]. Previously, we used recom-
binant DNA technology to define the minimum catalytic
core of protein Ser/Thr phosphatases and showed that it is
roughly equivalent to the bacteriophage lambda phos-
phatase [30]. Recombinantly expressed catalytic cores of
PP1 and PP5 indeed exhibited unregulated enzymatic
activities resembling those of the lambda phosphatase,
i.e., they retained phosphatase activity but lost interaction
with effectors and inhibitors [30]. For example, while PP1
is OA-sensitive, a truncated PP1 containing exclusively the
lambda-homology region, is resistant [30]. The PP5 phos-
phatases contain a TPR domain near the N-terminus that
is autoinhibitory; however, the enzyme could be activated
by the interaction of unsaturated fatty acids with the TPR
domain, which is a distinguishing characteristic of PP5
[38,39]. P. falciparum also has a PP5 ortholog with N-ter-
minal TPR domains, deletion of which indeed resulted in
elevated phosphatase activity accompanied by loss of acti-
vation by fatty acid [40,41].
Similar conclusions were reached by proteolytic analysis
of phosphatases. The lambda phosphatase, representing
the catalytic core with a compact structure [29], was highly
resistant to trypsin in vitro [30]. In PP5, removal of the TPR
domain by protease treatment resulted in increased
activity [40]. A large body of literature also exists on the
proteolysis of calcineurin, arriving at a similar conclusion.
Tryptic digestion of human calcineurin in vitro led to the
loss of the 17 kDa C-terminus of the CnA subunit includ-
ing the CaM-binding and autoinhibitory domains
[14,18,42]. The resultant fragment was essentially equiva-
lent to the catalytic core and was highly active; however, it
was no longer stimulated by Ca+2 and CaM. The tryptic
cleavage in human CnA occurred after residue 392 [42],
which is almost exactly the same region where PfCnA is
also cleaved (Fig. 1). As shown in Fig. 1, the CnB-binding
domain is contained in the processed PfCnA, which
explains why the processed calcineurin purified from the
parasite retained its heterodimeric nature [31]. Finally, as
Stimulation of the phosphatase activity of PfPP7, but not  PfPPJ, by Ca+2 Figure 8
Stimulation of the phosphatase activity of PfPP7, but not 
PfPPJ, by Ca+2. The histone dephosphorylase activities of 
recombinant PfPP7 (open circle) and PfPPJ (closed circle) 
were measured as described in Methods. Each data point is a 
mean of three measurements with the error bar as shown.
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mentioned before, crystal structure of the trypsin-resistant
human CnA-CnB in complex with cyclophilin-
cyclosporin (CyP-CsA) was determined, which led to the
identification of amino acid residues of CnA and CnB that
play an important role in CyP-CsA interaction [24]. These
residues are marked with asterisk in Fig. 1 and 2, respec-
tively, and it is clear that the processed P. falciparum subu-
nits retain all such residues. This explains why the
processed Pf CnA-CnB heterodimer dimer retained the
CyP-CsA sensitivity of the full-length enzyme (Table 1).
Enzymatic assays showed that the analogous trypsin-
resistant core of the human CnA-CnB also retained CyP-
CsA sensitivity [43]. Clearly, constitutively active, unregu-
lated catalytic cores could be produced from full-length
enzymes.
In this paper, we provide evidence that this indeed hap-
pens in vivo. Nearly two decades ago, a preliminary report
suggested processing of CnA in T cells by a Ca+2-depend-
ent protease [44]; however, the generality or the exact
mechanism of such processing was not investigated fur-
ther. While this paper was in preparation, evidence was
presented that during excitotoxicity in human neuronal
cells, calcineurin A (CnA) is directly cleaved by the Ca+2-
dependent cysteine protease, calpain. The in vivo cleavage
could be inhibited by calpain inhibitors, calpastatin and
ALLM (N-acetyl-Leu-Leu-methioninal) [45]. Although
multiple products were produced by cleavage at C-termi-
nal sites that were close to each other, the smallest frag-
ment was a result of cleavage between the two basic
residues, Arg392 and Lys393 (Fig. 1). As mentioned,
processing in this region produces a Ca+2-independent
phosphatase with higher basal activity. Recombinant
overexpression of this processed fragment or constitu-
tively active CnA in the neuronal cells led to apoptosis,
characteristic of excitotoxic neurodegeneration [45]. The
proteolytic activation of a Ca+2-activated phosphatase by
a Ca+2-dependent protease was proposed as an intriguing
regulatory pathway, responding to certain pathological
states.
Thus, the plasmodial CnA is processed in a region where
proteolytic processing has been known to occur in other
CnA homologs. We have tentatively assumed that the
processing observed for plasmodial CnA, CnB and PP7 are
proteolytic phenomena based on the facts that the
processing increases with time and can be partially inhib-
ited by traditional protease inhibitors. As revealed in these
immunoblots, significant processing occurred even in
freshly isolated parasites and in parasites that are still
inside the host RBC.
Unraveling of the exact mechanism of the processing
event(s) will clearly require more extensive studies. Auto-
proteolysis or self-cleavage is ruled out because the puri-
fied recombinant proteins did not undergo self-
processing in vitro (lane 3 in Fig. 3,4,7). A role of the Plas-
modium proteasome [46] seems unlikely because neither
MG132 nor lactacystin inhibited the processing in vivo or
in vitro (data not shown). The particular protease inhibitor
cocktail used here (see Methods) is claimed to inhibit
serine, cysteine, aspartic and metalloproteases as well as
calpain, the protease responsible for the processing of
human CnA mentioned above. However, we have not
been able to completely stop the processing of the plas-
modial enzymes with this cocktail in vitro as well as in vivo
(Figs. 3,4,7). At this time, we tend to believe that the
processing is catalyzed by plasmodial protease(s) that
may be at least partially resistant to the traditional pro-
tease inhibitors. A PlasmaDB query using the term "pro-
tease" reveals nearly two dozen proteases; however, a
recent study has suggested the existence of as many as 92
protease genes in P. falciparum by sequence homology, at
least 88 of which have been validated at the transcrip-
tional level [47]. One of these is a potentially novel cal-
pain-like protease that lacks a Ca+2-binding EF hand and
therefore, appears to be Ca+2-indepenedent [47]. It is also
to be noted that multiple proteases often act in concert to
extensively cleave a substrate protein. For example, cleav-
age by acidic cysteine, aspartic, and metalloproteases fol-
lowed by a neutral aminopeptidase results in the
complete hydrolysis of hemoglobin into single amino
acids [48]. Proteolytic cleavage of cytoskeletal proteins by
cysteine and aspartic proteases is also important in eryth-
rocytic rupture and invasion [49]. Based on these findings,
we propose that an atypical calpain and other unique
plasmodial proteases may be responsible for the
processing of parasitic CnA, CnB and PP7 phosphatases,
perhaps through a combination of endo- and exo-proteo-
lytic reactions. A number of cysteine proteases of P. falci-
parum, including a calpain-like protease, are expressed
mainly in the schizont stage. As schizont is a stage of high
metabolic activity and a prelude to gametogenesis, it
raises the intriguing possibility that the processing of cal-
cineurin and PP7 occurs mainly at this stage. In any case,
it is unlikely that this processing simply reflected a
universal protein degradation as it happened in specific
regions of the proteins and was not seen in many other
plasmodial proteins that we and others have studied over
the years. PfPP1 [50] was retested as one such negative
control; self-incubation of the parasite or incubation of
the recombinant PP1 with parasitic extract did not reveal
any degradation of PP1 (data not shown).
In summary, we have shown that specific post-transla-
tional cleavage of plasmodial protein phosphatases in vivo
can generate kinetically stable products that are more
active and less regulated than their unprocessed precur-
sors. Whether the processing itself is regulated during theBMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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erythrocytic development cycle of the parasite would be
an interesting query to answer.
Conclusions
Protease treatment of phosphatases in vitro is known to
result in the loss of regulatory domains and production of
protease-resistant catalytic cores. We provide biochemical
evidence of such post-translational processing in the pro-
tease-rich parasite, P. falciparum, whereby smaller phos-
phatases were rapidly generated from larger phosphatase,
most likely through proteolytic cleavage. While the larger
enzymes had regulatory domains that allowed their acti-
vation by Ca+2, the smaller counterparts were devoid of
such domains and hence, were constitutively active. The
processed enzymes approximated the protease-resistant
catalytic cores of the phosphatases generated in vitro. The
rapidity of the processing strongly suggested that this
occurred in the parasite cells in vivo and was, therefore,
physiologically relevant. It will be interesting to investi-
gate the generality of such post-translational processing
and its effect on the cellular proteome.
Methods
Recombinant proteins, peptide antibodies and 
immunoblot
The open reading frames (cDNA) of the proteins were
amplified by RT-PCR using the primers shown in Table 2.
The N-terminally His-tagged P. falciparum CnA and PP7
proteins were expressed using the pET15b vector, and the
C-terminally His-tagged CnB was expressed from the
pET23a vector (Novagen). All recombinants were
expressed in E. coli BL21(DE3) containing pMICO by
IPTG induction as described [51] and the soluble fraction
of the bacterial extract was used as the source of the
recombinant proteins. All three recombinants were puri-
fied by Ni+2-agarose chromatography as described in the
manufacturer's protocol (Novagen); the His-tag antibody
was also purchased from the same manufacturer.
Peptide sequences marked in the respective Figures were
synthesized and antibodies were raised in rabbits using
standard procedures as described [31]. SDS-PAGE and
immunoblot (Western) using chemiluminescence-based
detection were performed essentially as described [40].
Mass spectrometry (MALDI-TOF) was carried out at the
Proteomics Core facility and N-terminal microsequencing
were performed as described [31,33]. Where mentioned,
immunoblot bands were digitally scanned in a Fujifilm
LAS-1000 Intelligent Dark Box II Image Reader (Fujifilm,
Edison, NJ), and the intensities integrated and added
using the Image Gauge v4.0 software.
Growth, lysis and analysis of P. falciparum
P. falciparum (3D7) was grown in human A-positive eryth-
rocytes and infected cells were harvested at about 15%
parasitemia and lysed by the saponin method essentially
as described [51]. The processed PfPP2B (calcineurin) and
PPJ were purified from the parasites using procedures
established previously [31,33]. In brief, the parasites were
either processed immediately or held at room tempera-
ture for various times, and unless otherwise mentioned,
all subsequent fractionation procedures were performed
in cold or with ice-cold buffers. The parasite cell pellet was
resuspended in buffer A (50 mM Tris-Cl, pH 7.5, 10%
glycerol, 1 mM DTT, 20 mM NaCl) plus 1% Triton X-100
and the "complete protein inhibitor cocktail" (Roche);
one mini tablet was dissolved per 10 ml of buffer A as pre-
scribed by the manufacturer. The suspension was soni-
cated and the lysate clarified by a brief centrifugation at
15,000 × g for 5 min in a refrigerated centrifuge. For SDS-
PAGE and immunoblot, about 50 µg of this lysate was
analyzed in each lane.
To test for parasitic proteolytic activity in vitro, a similar
extract was made except that the protease inhibitor was
omitted. About 100 ng of the appropriate recombinant
protein was incubated with 1 µl of 1:10 dilution of the
uninhibited extract in buffer A for 10 min at room temper-
ature followed by SDS-PAGE and immunoblot analysis.
Table 2: Primers used for amplification and cloning of the phosphatase cDNAs
cDNA cloned Primer pair
PfCnA N6CTCGAGGAACCACTGCCTGATCCGAAG
N6GGATCCTTATTCGTTGGATGGCCTCTTTTCGT
PfCnB N6GCTAGCATGGGAAACACACAAGCGATATTATC
N6CTCGAGTAATTCTAGCTTCAATTTATTTCCAAC
PfPP7 N6CTCGAGGAAAATTACAACATTGAAGATGTTG
N6GGATCCTTAATTATTTGAATATATATATGTAGGC
In each pair, the first primer is the 5' sense primer, and second one is the 3' antisense primer. All primers contained a random hexanucleotide 
sequence (N6) for efficient restriction of the PCR product, followed by restriction sites (underlined): XhoI (CTCGAG), BamHI (GGATCC), NheI 
(GCTAGC). All sequences are written 5' → 3'. Note that the natural start codons (ATG) of both PfCnA and PfPP7 were removed because 
translation would originate from the upstream ATG of the pET-15b vector (in order to add the N-terminal His-tag). In PfCnB, the ATG was left 
intact but the stop codon was removed so that translation could continue into the pET-23a vector to add the C-terminal His-tag.BMC Molecular Biology 2004, 5:6 http://www.biomedcentral.com/1471-2199/5/6
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Phosphatase assay
32P-labeled phosphohistone was made by phosphoryla-
tion of histone with the catalytic subunit of protein kinase
A and was used as substrate for phosphatase assay essen-
tially as described previously [40]. Standard assays were
performed in buffer A, and additional activators or inhib-
itors were added only where mentioned. Reactions were
incubated at 37°C. Reactions were carried out in 80 µl fol-
lowed by quantification of the liberated 32Pi by phospho-
molybdate extraction assay. Reactions were followed with
time to ensure linearity, and results were corrected by sub-
traction of the corresponding values from an enzyme-free
reaction. Phosphatase reactions were routinely initiated
with the addition of substrate. Where indicated, the fol-
lowing additions were made at the indicated concentra-
tions 10 minutes prior to initiating the reaction with the
addition of substrate: Ca+2, Mg+2, Mn+2 (2 mM each), cal-
modulin (CaM, 1 µM,), CyP (recombinant PfCyP19, 1
µM), cyclosporin A (CsA, 1 µM), OA (0.2 µM) [31,33].
Use of cyclosporin A (CsA) and recombinant P. falciparum
cyclophilin 19 (CyP19) for calcineurin inhibition assay
has been described before [31]. One unit of phosphatase
activity was defined as nanomoles of phosphate liberated
per min at 37°C. The processed recombinants were
obtained by complete proteolytic digestion as in Fig.
3,4,6, except that incubation was carried out for 20 min to
ensure maximum proteolysis; the preparations were
essentially free of full-length proteins as monitored by
SDS-PAGE (data not shown). The endogenous (proc-
essed) calcineurin was purified from the parasite essen-
tially as described [31] and was at least 80% pure with no
single contaminant exceeding 10% as judged by SDS-
PAGE and staining.
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